SUPERNUS PHARMACEUTICALS, INC.
SUPERNUS PHARMACEUTICALS, INC. (SUPN): 22 pipeline candidates · 9 upcoming catalysts · ~6 mo cash runway · 15 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
6.4 months
D/E 0.39 · 0% dilution
Lead: Approved
22 candidates
9 upcoming, next in ~137d
0 buys · 17 sells (180d)
A transparent, data-derived signal for SUPERNUS PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.5B
Cash
$186.3M
Quarterly Burn
$164.6M
Runway
6.4 mo
Revenue
$207.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (22 candidates)
| Drug | Phase |
|---|---|
| 100mg SPN-812 | Phase 4 |
| APOKYN | Approved |
| GOCOVRI | Approved |
| Memantine | Phase 4 |
| Memantine Hydrochloride | Phase 4 |
| Memantine Oral Tablet | Phase 4 |
| MYOBLOC | Approved |
| nv-5138 | Phase 2 |
| ONAPGO | Approved |
| Oxtellar XR | Approved |
Showing 10 of 22 candidates. Sign up for full pipeline.
Upcoming Catalysts (9)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
327
Total value held
$3.06B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,797,254 | $454.7M |
| vanguard capital management llc | 4,934,430 | $255.1M |
| millennium management llc | 3,315,973 | $171.4M |
| vanguard portfolio management llc | 3,238,693 | $167.4M |
| dimensional fund advisors lp | 2,307,030 | $119.2M |
| state street corp | 2,288,127 | $118.3M |
| nomura asset management international inc. | 2,037,202 | $105.3M |
| armistice capital, llc | 1,895,347 | $98.0M |
| renaissance technologies llc | 1,705,222 | $88.1M |
| geode capital management, llc | 1,623,514 | $83.9M |
Showing top 10 of 327 institutional holders of SUPERNUS PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SUPERNUS PHARMACEUTICALS, INC.'s pipeline?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) has 22 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SUPERNUS PHARMACEUTICALS, INC.'s lead drug candidate?
SUPERNUS PHARMACEUTICALS, INC.'s most advanced tracked candidate is 100mg SPN-812 (Phase 4) for Attention-Deficit/Hyperactivity Disorder.
What is SUPERNUS PHARMACEUTICALS, INC.'s next catalyst?
SUPERNUS PHARMACEUTICALS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: LYRICA CR" — expected November 2, 2026.
What is SUPERNUS PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SUPERNUS PHARMACEUTICALS, INC. has approximately 6.4 months of cash runway.
What is SUPERNUS PHARMACEUTICALS, INC.'s market capitalization?
SUPERNUS PHARMACEUTICALS, INC.'s market capitalization is approximately $2.5B.
Get the full picture on SUPERNUS PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.